RxDoctor Payments Data

Aaron Petrey, PA

Medical · Williamsburg, KYNPI 1710525944

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 181 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 20.5% — the pattern of someone who eats at a lot of different presentations.

$2,879in general payments, 2019–2025

Across 181 payments — averaging $15.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$589
  • AstraZeneca$405
  • Bayer$345
  • Novo Nordisk$191
  • Evoke Pharma, Inc.$163
  • Amgen$150
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$2,879100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,879 in reported general payments places this provider in the 70th percentile of 222 medical providers in Kentucky.

See all medical providers in Kentucky

Medicare billing

Part B allowed, 2024
$221
Medicare patients
19
Services billed
24

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide150$138,418
MounjaroTirzepatide91$103,635
Breztri AerosphereBudesonide/Glycopyr/Formoterol89$61,639
JardianceEmpagliflozin60$43,756
EliquisApixaban58$41,393
FarxigaDapagliflozin Propanediol56$34,678
XareltoRivaroxaban53$31,902
VraylarCariprazine Hcl18$25,245
UbrelvyUbrogepant21$21,615
RexultiBrexpiprazole11$18,679
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$17,743
JanuviaSitagliptin Phosphate17$11,760
LinzessLinaclotide18$10,290
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog28$8,165
Levemir FlexpenInsulin Detemir34$7,100

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$191$138,418150 claims
Lilly USA, LLCMounjaro, Olanzapine$62$104,471121 claims
AstraZenecaBreztri Aerosphere, Farxiga, Brilinta$405$103,361161 claims
AbbVieVraylar, Ubrelvy, Linzess$589$57,15057 claims
GSKTrelegy Ellipta, Shingrix$131$23,70055 claims
Otsuka America Pharmaceutical, Inc.Rexulti$24$18,67911 claims
MerckJanuvia$116$11,76017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 222 medical providers in Kentucky.

Other medical in Williamsburg

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →